InvestLog
Back to Market返回行情

ATHA Athira Pharma, Inc.

NASDAQHealthcare
$6.75-6.12%ClosedMarket Cap: $26.6M

As of 2026-01-09 16:00

Why ATHA matters now

Athira Pharma, Inc. (ATHA) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.75 with -6.12% on the session and $26.6M in market capitalization.

The latest indexable market news headline is "ATHA Energy Reports Widest Intersection to Date at Rib North Discovery with 37 m of Composite Uranium Mineralization in Ribn-DD-003 – Multiple Drillholes Demonstrating Continuity of Uranium Mineralization" from Accesswire.

Latest News

ATHA Energy Reports Widest Intersection to Date at Rib North Discovery with 37 m of Composite Uranium Mineralization in Ribn-DD-003 – Multiple Drillholes Demonstrating Continuity of Uranium MineralizationAccesswire · 2026-07-09
ATHA Energy Makes Major New High-Grade Discovery along the Lac 50 Corridor - Intersects 11.5 m of Composite Uranium Mineralization Including 1.6 m of Near Continuous High-Grade 4 km Along Strike from Lac 50 Deposit AreaAccesswire · 2026-07-08
OTC Markets Group Welcomes ATHA Energy Corp. to OTCQXGlobeNewsWire · 2026-06-30
Athena Gold Provides Exploration Update from Excelsior Springs, NevadaNewsfile Corp · 2026-06-16
Athena Provides Updates Across Gold PortfolioNewsfile Corp · 2026-06-09

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

NASDAQ

Beta

2.80

Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease. Additionally, ATH-1017 is in Phase 2 clinical trials for Parkinson's disease. The company also has several product candidates in earlier, preclinical stages of development, including ATH-1019 for conditions affecting the peripheral nervous system and ATH-1020 for neuropsychiatric disorders. Founded in 2011, the organization was known as M3 Biotechnology, Inc. until it rebranded to Athira Pharma, Inc. in April 2019.